Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 1 23Phase 1/2 8Phase 3 6Phase EARLY_PHASE1 2Phase 4 2Phase 2/3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 5Pancreatic Neoplasms 2Glioblastoma 2Breast Neoplasms 2Sarcoma 1Recurrence 1Prostatic Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

Letrozole 7Fluorodeoxyglucose F18 7Magnetic Resonance Spectroscopy 5Blood Specimen Collection 5pembrolizumab 4atezolizumab 4Trastuzumab 4Oncolytic Virotherapy 4Bevacizumab 4palbociclib 3Saline Solution 3Fish Oils 3Docosahexaenoic Acids 3Denosumab 3Carboplatin 3Biopsy 3pertuzumab 2olaparib 2Vitamin D 2Vinorelbine 2Taxes 2Sentinel Lymph Node Biopsy 2Radiotherapy 2Positron-Emission Tomography 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Omacor 2Neoadjuvant Therapy 2Metformin 2Lapatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Breast Neoplasms × olaparib × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04041128 2023-03-20

PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer

University of Texas Southwestern Medical Center

Phase EARLY_PHASE1 Completed
14 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡